Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is being done to check how safe and comfortable LCFA-01 is when used inside the vagina. LCFA-01 is a natural product that contains oleic acid, and it comes as a soft gel capsule that participants will place in the vagina using their fingers.
The main purpose of the study is to make sure the product is safe and does not cause any problems or discomfort. The study will also measure how much of the product stays in the vagina and whether any of it enters the bloodstream. This helps researchers understand how the body absorbs and handles the product.
Finally, the study will also look at early signs of how the product might affect the natural bacteria in the vagina.
In the future, LCFA-01 may be used to treat bacterial vaginosis (BV).
This study is testing a new vaginal product called LCFA-01 for the first time in humans. The goal is to see:
Up to 30 healthy adult women who are 18 years to 40 years of age and who are not pregnant & not in menopause.
Women first go through a "Screening period" lasting up to 35 days. Doctors make sure they are healthy and can join the study.
The whole study period lasts 2 weeks:
Week 1: Using the product
Women use the vaginal product once a day for 7 days. Day 1 and Day 2: They use it at the clinic, so doctors can watch closely for safety.
Day 3 to Day 7: They use it at home.
Women also take their own vaginal swab samples every day at home. During the first week, they take the swab before using the product.
Week 2: No product
Women stop using the product but continue to self-swab at home. They come back for a check-up at the end of this week.
There will be 2 groups (cohorts), each trying a different amount of LCFA-01:
In each group, 2 out of 3 women get LCFA-01
1 out of 3 gets a placebo (a harmless, inactive product)
This helps researchers compare effects.
Only 2 women (one gets LCFA-01, one gets placebo) are treated first in each group.
Doctors watch them for 24 hours. If everything looks safe, the rest of the women in that group can begin the study.
Are there any side effects? Is the product safe and comfortable to use? Does any of the product get into the bloodstream? How long does the product stay in the vagina? How does it affect the vaginal environment?
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LCFA-01 | Experimental | Dose 1 (200 mg) Dose 2 (400 mg) Dose Formulation- The soft gelatin capsule is light-to-medium yellow in color and oblong in shape Route of Administration- Vaginal |
|
| Placebo | Placebo Comparator | Route of Administration- Vaginal |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LCFA-01 | Drug | LCFA-01 Drug Product is a soft gelatin capsule, containing oleic acid at 2 dosage strengths (200 mg and 400 mg). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-emergent adverse events (TEAEs) | Day 1 to Day 14 | |
| Clinically significant changes in Physical examinations | Baseline, Day 2, Day 8, Day 10, Day 14 | |
| Clinically significant changes in Vital Signs as per protocol | Baseline, Day2, Day 8, Day 10, Day 14 | |
| Clinically significant changes in Safety Laboratory Parameters as per protocol | Baseline, Day 1, Day 2, Day 8, Day 10 | |
| Self-Reported Symptoms-abnormal vaginal odor | Baseline to Day 14 | |
| Self-Reported Symptoms-pain, tenderness | Baseline to Day 14 | |
| Self-Reported Symptoms- dyspareunia | Baseline to Day 14 | |
| Self-Reported Symptoms- dysmenorrhea/cramping with menses | Baseline to Day 14 | |
| Self-Reported Symptoms- vaginal vulvar itching | Baseline to Day 14 | |
| Self-Reported Symptoms-vulvar edema | Baseline to Day 14 | |
| Self-Reported Symptoms- vulvar erythema |
| Measure | Description | Time Frame |
|---|---|---|
| PK parameters derived from plasma concentration for Maximum concentration (Cmax) | On Day 1, 2, 8, 10 | |
| Observed concentrations of LCFA-01 in vaginal samples post-dosing | Day 1, 2, 8, 10, 14 | |
Not provided
Inclusion Criteria:
receptive oral sex anal sex vaginal sex toys
Exclusion Criteria:
Women who currently have moderate or severe vaginal symptoms (such as pain, itching, burning, or unusual discharge) at the Screening visit cannot join the study.
Women with physical or mental health conditions that, in the opinion of the study doctor, would make it difficult for them to follow the study rules or finish the study will not be able to participate.
Women who have had certain surgeries, such as:
removal of the uterus (full or partial hysterectomy) major surgeries on the cervix, vagina, or uterus (for example: cervical cone biopsy,removal of the cervix, or major uterine surgery)
cannot participate because these procedures may change the vaginal or reproductive anatomy, which could affect study results.
Women with certain medical conditions, including:
a. Serious diseases of the vagina, cervix, or uterus, such as:
cancers of the female reproductive system
endometriosis
chronic or recurrent vaginal infections
b. Uncontrolled genital herpes, meaning they had at least one active outbreak in the past 6 months.
c. Serious health problems such as: heart disease or a past heart attack chronic lung disease (like COPD) chronic kidney failure severe liver disease (cirrhosis) or any other serious condition that the study doctor believes would make it unsafe to join the study.
d. Any condition that would require using steroid medicines inside the genital area during the study. (Steroid creams used on the skin, inhalers, or nose sprays are allowed.) e. A yeast infection (vulvovaginal candidiasis) found during Screening. f. Repeated episodes of bacterial vaginosis (BV), meaning two or more episodes in the past year.
Women who have ever had an autoimmune disease cannot join the study.
Autoimmune diseases happen when the body's immune system attacks its own tissues. Examples include:
Hashimoto's thyroid disease Pernicious anemia Addison's disease Rheumatoid arthritis Lupus Multiple sclerosis Myasthenia gravis Grave's disease Celiac disease Psoriasis Sarcoidosis Scleroderma Diabetes (Type 1)
This includes:
vaginal douching using products to clean, wash, dry, or "freshen" the vagina
an Intravaginal Product, hence only Women will be participating
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dr Douglas Kwon | Contact | +18572687160 | dkwon@mgh.harvard.edu |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Allied Health Hub Morayfield | Recruiting | Brisbane | Queensland | 4506 | Australia |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | LCFA-01 Placebo is a soft gelatin capsule, of which the composition is similar to that of LCFA-01 Drug Product, but without the active pharmaceutical ingredient. |
|
| Baseline to Day 14 |
| Self-Reported Symptoms-vulvar lesions | Baseline to Day 14 |
| Self-Reported Symptoms-Bartholin or Skene's gland lesions | Baseline to Day 14 |
| PK parameters derived from plasma concentration for Area Under the Curve (AUC) |
| On Day 1, 2, 8, 10 |
| PK parameters derived from plasma concentration for Time to maximum concentration( Tmax) | On Day 1, 2, 8, 10 |